|Bid||17.85 x 900|
|Ask||18.50 x 2200|
|Day's range||17.61 - 19.25|
|52-week range||17.11 - 236.50|
|Beta (5Y monthly)||1.88|
|PE ratio (TTM)||N/A|
|Earnings date||02 Nov 2022 - 07 Nov 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||105.83|
Despite being the first protein-based COVID-19 vaccine in many markets, Novavax's (NVAX) delayed product launch severely affected the company's prospects.
Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Novavax (NVAX) closed the most recent trading day at $18.20, moving -1.99% from the previous trading session.